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This study objective was to evaluate the cytokines associated with early events of hepatic fibrosis in schistoso-
miasis mansoni. Hepatic fibrosis was classified by ultrasonography in 94 patients. Immunological evaluation was
performed by measurement of secreted cytokines (interleukin IL-5, IL-10, IL-13, interferon-γ, tumor necrosis factor-
α and transforming growth factors-β) in peripherl blood mononuclear cells stimulated by Schistosoma mansoni
antigens. Significantly, higher levels of IL-5, IL-10 and IL-13 were found in supernatants of SEA-stimulated PBMC
from subjects with degree III hepatic fibrosis as compared to patients with degree I or II fibrosis, Significant in-
creases in IL-5 and IL-13 levels were also observed in some of the subjects who remained untreated for one year
following initial assessment and developed more serious fibrosis during this period. The data suggests a role for
type 2 cytokines in early stages of hepatic fibrosis in human schistosomiasis mansoni.
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 The pathology resulting from infection with the helm-
inth parasite Schistosoma mansoni is predominantly
caused by the host immune response to parasite eggs
that are laid in the portal venous system, and which be-
come trapped in hepatic sinusoids and sequestered within
granulomatous lesions (Warren 1968,  Pessoa & Martins
1978,  Cheever et al. 1994, Bica et al. 2000, Chiaramonte et
al. 2001, Monica et al. 2003). The fibrosis associated with
granuloma formation can lead to portal hypertension,
which causes much of the morbidity and mortality associ-
ated with schistosomiasis (Doumenge 1987).
The formation of granulomas around schistosome
eggs is mediated by CD4+ T cells (Warren et al. 1967). In
the murine model of schistosomiasis, type 2 associated
cytokines, including interlukin (IL-4, IL-5, IL-13) contrib-
ute to granuloma formation and the presence of eosino-
phils in these lesions (Chiaromonte et al. 2001). However,
in human schistosomiasis, studies have shown that high
levels of tumor necrosis factor-α and low levels of inter-
feron-γ produced by in SEA stimulated peripheral blood
mononuclear cells (PBMC) are significantly associated
with the presence of severe liver fibrosis (Mwatha et al.
1998, Henri et al. 2002, Booth et al. 2004). As hepatoesplenic
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disease is a long-term complication of this schistosomia-
sis mansoni, it is conceivable that the immune mecha-
nisms responsible for this lesion occur much earlier dur-
ing infection and precedes the downstream development
of hepatosplenomegaly. Consequently, it is important to
evaluate the immune response in the early events of he-
patic fibrosis. In the present study the cytokine profiles
in supernatants of soluble egg Ag-stimulated PBMC from
schistosomiasis patients with different stages of hepatic
fibrosis were measured, and an association between type
2 cytokine production and progression to fibrosis was
detected.
MATERIALS AND METHODS
Endemic area, subjects selected and ultrasonogra-
phy - This study included 94 patients with schistosomia-
sis who had their degrees of fibrosis determined by ultra-
sonography. The majority of the patients (n = 79) were
selected from Caatinga do Moura, at the village endemic
for schistosomiasis mansoni, located at 380 km from Sal-
vador, Bahia. A constant aquatic exposure is observed in
a large part of the population. Because there were few
patients with degree III hepatic fibrosis in Caatinga do
Moura, more patients with degree III fibrosis were recruited
from two other endemic areas of schistosomiasis: Ta-
quarendi (n = 9) another village, located at 30 km from
Caatinga do Moura, and Maruim (n = 6), a village from the
state of Sergipe, north of the state of Bahia. All field sites
are not endemic for malaria, leishmanaisis or Chagas dis-
ease but have other intestinal parasitic infections such as
Ascaris lumbricoides, Thichiuris trichiura, Ancylostoma
duodenale, Entamoeba coli, Entamoeba histolytica, and
Giardia lamblia. All patients with degree III of hepatic
fibrosis had small spleen sizes (1 to 3 cm of the left costal
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ribs) and no past digestive bleeding or other signs of
severe portal hypertension. The inclusion criteria were to
have positive Kato-Katz parasitological examinations for
schistosomiasis, no history of therapy for schistosomia-
sis in the last 3 years, and hepatic fibrosis as assessed by
ultrasonography. Exclusion criteria included being under
4 or above 60 years or having positive serology for HIV
(human immunodeficiency virus), HTLV-1 (human T cell
leukemia virus type I)  or hepatitis virus type B and C, as
well as other conditions that could interfere in the immu-
nological evaluation or ultrasonographycal classification.
Clinical and parasitological stool exams are performed in
these populations every 3 years, followed by specific treat-
ment for S. mansoni with oxaminiquine (20 mg/kg of
weight). All patients or the guardians of minors signed an
informed consent and the study was approved by the
Ethical Committee of the Hospital Universitário Prof.
Edgard Santos.
Ultrasonographical examination - Were performed
using the WHO criteria established in 1993 for classifica-
tion of hepatic fibrosis, (Abdel-Wahab et al. 1992, de Jesus
et al. 2000). This classification considers degree 0, if peri-
portal tract is < 3 mm; degree I, if it is from 3 to 5 mm;
degree II, if it is from > 5 to 7 mm; and degree III, if it is > 7
mm. These exams were performed by two independent
persons, and we have shown a correlation between peri-
portal thickness and portal vein diameter and spleen size
(de Jesus et al. 2000). Twenty-one of these subjects who
failed to be treated, even after several attempts to localize
them for schistosomicidal drugs, were re-evaluated by
ultrasonographical exam after one year of the first evalu-
ation. Nineteen of these patients had shown an increase
in the periportal tract thickness, but in only 12 had this
increase induced a change in their degrees of hepatic fi-
brosis. For 3 patients, this had changed from degree 0 to
I and for 9 patients, this had changed from degree I to II.
One year after treatment with oxaminiquine, all patients
had improved and returned to degree 0 or I of fibrosis (de
Jesus et al. 2000).
Immunological methods - PBMC were isolated from
heparinized blood by density gradient centrifugation us-
ing histopaque 1077 (Sigma Diagnostic, St. Louis, MO) as
previously described (Ribeiro de Jesus et al. 2000) and
were left without stimulus or were stimulated with S.
mansoni specific antigens: soluble extract of whole adult
S. mansoni SWAP (10 µg/ml) and soluble extract egg Ag,
SEA (10 µg/ml), prepared as previously described (Pearce
et al. 1986, Ribeiro de Jesus et al. 2000). The optimal con-
centration was determined previously by testing unin-
fected controls from Salvador. Levels of the cytokines
(IL-5, IL-10, IFN-γ, TGF-β, IL-13, and TNF-α) were mea-
sured in supernatants using sandwich ELISAs, and the
results were expressed as pg/ml, based on comparisons
with standard curves, according to a previously described
technique (Ribeiro de Jesus et al. 2000,  2002). Commercial
kits from R&D  (R&D systems Inc. Minneapolis, MN, US)
were used for IFN-γ, IL-10, TNF-α, IL-13, and TGF-β. Duo
set antibodies (PharMingen, San Diego, CA, US) were
used to test IL-5. Immulon 2 ELISA plates were from
Dynatech (Dynatech Laboratories, Inc., US). The sensi-
tivity cut-offs for the ELISAs for each of the cytokines
were: 30 pg/ml for IFN-γ, IL-5, IL-10, and TNF-α; 14 pg/ml
for IL-13 and 7 pg/ml for transforming growth factor-β.
The results considered for analysis were the differences
of cytokine concentrations from the supernatants of stimu-
lated culture versus unstimulated PBMC cultures.
Statistical methods - The differences in all variables
analyzed between the groups of subjects with degrees I,
II, and III of hepatic fibrosis were analyzed by the Mann-
Whitney test. A non-parametric test was chosen because
the data did not follow a Gaussian distribution. The dif-
ferences in cytokine levels in the group of patients who
increased the degree of fibrosis in 2 consecutive evalua-
tions were compared by Wilcoxon signed rank test for
matched groups. These statistical analyses were per-
formed using the program Instat for Machintosh. An α
value of 5% was considered for significance.
RESULTS
Description of the study groups - The 94 schistoso-
miasis patients selected for study had an age range of 5 to
55 with mean and standard deviation of 16 ± 8, with 46
male and 48 females. Their infection levels ranged from 24
to 1784 e.p.g of feces. According to ultrasonographycal
examination, 8 subjects were classified as degree 0, 50 as
degree I, 22 as degree II, and 14 as degree III of hepatic
fibrosis. The age, sex, and infection levels in the sub-
groups of patients with different degrees of hepatic fibro-
sis are described in the Table. Patients with degree 0 and
I of hepatic fibrosis were included in the same subgroup.
TABLE
Demographic data and infection intensity for schistosomiasis subjects with different degrees of hepatic fibrosis classified by
ultrasonography
        Degrees of hepatic fibrosis
 0 - I II III
Number of patients   58 22 14
Age range    5-55   9-45   7-50
Mean age ± standard deviation (SD)       16 ± 11.5 a      21 ± 10.5 a   21 ± 13.3
Sex (M:F) 31:27 11:11 8:6
Range of number of eggs/g stool    24-1784    40-1616  24-216
Mean ± SD number of eggs/g stool  379 ± 426 b  412 ± 399 b  117 ± 98 b/c
a, b, c: p = 0.01
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Differences in age were observed between patients with
degrees 0-I (mean ± SD of 16 ± 11.5) and II (21 ± 10.5) of
hepatic fibrosis (p = 0.01, Mann-Whitney test). Differ-
ences in infection levels were also observed between the
patients with degrees I and III  (379 ± 426 and 117 ± 98,
respectively) and between degrees II and III (412 ± 399
and 117 ± 98, respectively) of hepatic fibrosis (p = 0.01,
Mann Whitney test).
The differences in the numbers of patients evaluated
for each cytokine reflects the limited availability of cul-
ture supernatants, which itself reflects the limited num-
bers of PBMC obtained.  Based on previous reports, we
prioritized the evaluation of IFN-γ (SWAP n = 94, SEA n =
62) TNF-α (SWAP n = 74, SEA  n = 56), and IL-5 (SWAP n
= 82, SEA n = 73), leaving less supernatants for the mea-
surement of IL-10 (SWAP n = 74, SEA n = 54), IL-13 (SEA
n = 39), and TGF-β (SEA n = 41).  Because patients were
treated after donating PBMC samples, we were unable to
perform repeat analyses. We were unable to assess IL-4
production due to the difficultly of measuring thus
cytokine in PBMC supernatants (Sabin et al. 1996).
Cytokine response to S. mansoni antigens - A great
variability in cytokine levels was observed in general,
showing the heterogeneity of the response to S. mansoni
antigens. A significantly (p = 0.03, Mann Whitney test)
higher level of IFN-γ was observed in supernatants of
SWAP-stimulated PBMC from patients with degree II (n =
23) versus degree I (n = 57) versus degree III (n = 14)
hepatic fibrosis (257 ± 354 versus 104 ± 189 vs 39 ± 58 pg/
ml, respectively). No significant differences in IFN-γ lev-
els were observed in supernatants from SEA stimulated
PBMC from the three groups of patients (79 ± 295.8, 3 ±
14.2 and 44 ± 79 pg/ml), (Fig. 1A). The levels of TNF-α in
SWAP and SEA-stimulated PBMC supernatants also did
not show any differences between the groups (Fig. 1B).
High levels of IL-5 were produced by SWAP-stimu-
lated PBMC from all groups of patients (degree I 1043 ±
1844.5, degree II 1319 ± 1706.7, and degree III 2219 ± 2011),
with significantly higher levels in patients with degree III
versus degree I fibrosis (p = 0.03, Mann Whitney test).
Levels of IL-5 were significantly lower in supernatants
from SEA-stimulated PBMC of subjects with degrees I
(93 ± 248.4 pg/ml) and II (11 ± 29.8 pg/ml) of hepatic fibro-
sis, than in supernatants from patients with degree III
hepatic fibrosis (669 ± 815.6pg/ml), (p = 0.01 and p = 0.009,
respectively, Mann Whitney test) (Fig. 2A). IL-13 levels
in supernatants of SEA stimulated PBMC were also higher
in subjects with degree III fibrosis (116 ± 120.9 pg/ml), as
compared to those with degrees I (24 ± 11.4 pg/ml) or II
(86 ± 166.5 pg/ml) of hepatic fibrosis, (p = 0.009 and p =
0.05, respectively, Mann Whitney test) (Fig. 2B). Levels
of IL-10 in SWAP- stimulated PBMC was not statistically
significant. Higher levels of IL-10 were observed in su-
pernatants of SEA-stimulated PBMC from patients with
degree III hepatic fibrosis (187 ± 110 pg/ml) compared to
those with degree I (63 ± 62.9 pg/ml) or II (66 ± 53 pg/ml) of
hepatic fibrosis (p = 0.01 and p = 0.03, respectively, Mann
Whitney test) (Fig. 3A). No differences were detected in
TGF-β levels in SEA-stimulated PBMC supernatants be-
tween the groups of patients with degrees I, II, and III
hepatic fibrosis. (Fig. 3B).
Fig.1: interferon-γ (A) and tumor necrosisfactor-α (B) levels in
SWAP and SEA-stimulated peripheral blood mononuclear cells su-
pernatants in schistosomiasis patients with different degrees of
hepatic fibrosis. Data represents the mean ± Standard Error (SEM).
a: p = 0.03; b: p = 0.02, Mann Whitney test
Fig. 2: interleukin-5 (A) and IL-13 (B) levels in SWAP and SEA-
stimulated peripheral blood mononuclear cells supernatants in schis-
tosomiasis patients with different degrees of hepatic fibrosis. Data
represents the mean ± Standard Error (SEM).  a: p = 0.03; b: p =
0.01; c: p = 0.009;  d: p = 0.0009;  e: p = 0.05, Mann Whitney test
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Responses of patients who remained untreated fol-
lowing initial assessment. Even after an active search, 21
patients missed treatment that should be performed at the
end of the study, and remained untreated after one year
from their first ultrasonography examination. Ultrasonog-
raphy was repeated on these individuals and 19 (90%) of
them were found to have increased periportal thickness
and 2 of them remained with similar measurements. Within
this group, 12/19 (57%) exhibited more severe fibrosis
compared to the previous exam. In 3 patients the fibrosis
index had changed from degree 0 to degree I, and in 9
patients the fibrosis index had increased from degree I to
degree II.  Immunological evaluation was repeated in these
patients and compared with the first evaluation. An in-
crease in the levels of some cytokines was observed in
SEA-stimulated PBMC supernatants. Levels of IFN-γ were
evaluated in 18 patients and 2 patient presented a de-
crease but the others did not show any significant change
in the second versus first evaluations (Fig. 4A). TNF-α
levels increased in 5 patients and decreased in 2 patients
and remained at similar levels in 8 of the 15 patients tested
(Fig. 4B). IL-5 levels increased in 9 patients, decreased in
1 patient and remained at similar levels in 8 of the 18 pa-
tients tested (Fig. 5A), and IL-13 levels showed a major
increased in 5 patients, a minor increase in 2 patients and
decreased or remained at similar levels in 2 of the 9 pa-
tients tested (Fig. 5B). The levels of IL-5 and IL-13 were
significantly higher in the second evaluation (206 ± 434
and 89.7 ± 56 pg/ml, respectively), in comparison to the
first evaluation (19 ± 62 pg/ml and 9.6 ± 11pg/ml, respec-
tively), (p = 0.03 and p = 0.04 respectively, Wilcoxon signed
rank test). IL-10 levels also increased in 7 of 13 patients,
decreased in 3 and remained at similar levels in other 3
patients (Fig. 6A), and TGF-β levels increased in 6 of 14
patients, decreased in 2 and remained at similar levels in
other 2 patients (Fig. 6B). No statistically significant dif-
ferences were observed in the levels of IFN-γ, TNF-α, IL-
10 and TGF-β in SEA-stimulated PBMC supernatants from
the second to the first evaluations (p = 0.4, p = 0.4, p = 0.3
and p = 0.4, respectively, Wilcoxon signed rank test). No
significant differences were observed between the levels
of cytokines in SWAP-stimulated PBMC supernatants
from the second to the first evaluations.
Fig. 3: interleukin-10 (A) and transforming growth factor-β (B)
levels in SWAP and SEA-stimulated peripheral blood mononuclear
cells supernatants in schistosomiasis patients with different degrees
of hepatic fibrosis. Data represents the mean ± Standard Error
(SEM). a: p = 0.01; b: p = 0.03, Mann Whitney test
Fig. 4:  interferon-γ (A) and tumor necrosis factor-α (B) levels in
SEA-stimulated peripheral blood mononuclear cells supernatants
from subjects who increased the periportal tract thickness after
one-year follow-up without treatment. a: Wilcoxon signed rank
test
Fig. 5: interleukin-5 (A) and IL-13 (B) levels in SEA-stimulated
peripheral blood mononuclear cells supernatants from subjects who
increased the periportal tract thickness after one-year follow-up
without treatment. IL-5 and IL-13 levels increased in (50%) of the
patients. a: Wilcoxon signed rank test
Fig. 6: interferon-10 (A) and tranforming growth factor-β (B) lev-
els in SEA-stimulated peripheral blood mononuclear cells superna-
tants from subjects who increased the periportal tract thickness
after one-year follow-up without treatment. IL-10 levels increased
in (39%), and TGF-β increased in (43%) of the patients. a: Wilcoxon
signed rank test.
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DISCUSSION
A type-2 cytokine pattern dominates the immune re-
sponse in mice and humans chronically infected by S.
mansoni. In mice, IL-4 and IL-13 play a major role in egg
granuloma formation, and IL-13 was shown to play a sig-
nificant role in the development of hepatic fibrosis
(Chiaramonte et al. 1999, 2001, Monica et al. 2003). In hu-
mans, although low IFN-γ and high TNF-α are associated
to severe hepatic fibrosis (Henri et al. 2002, Booth et al.
2004), it is still not clear which cytokines are involved in
the progression of schistosomiasis mansoni pathology.
The present study evaluated the cytokine profile in schis-
tosomiasis patients developing hepatic fibrosis in pre-
hepatosplenic and early hepatosplenic stages of the dis-
ease, and showed an association between a type 2
cytokine profile (the production of IL-5, IL-10, and IL-13)
and degree III hepatic fibrosis. IL-5 and IL-13 showed the
strongest association with severe hepatic fibrosis, and
also increased significantly in patients who exhibited in-
creased hepatic fibrosis after 1 year without treatment.
Besides these Th2 cytokines, TGF-β also increased in
about 50% of the patients who exhibit increased hepatic
fibrosis after 1 year without treatment. remained at similar.
However TGF-β levels did not differ in the groups with
different degrees of hepatic fibrosis.
Many variables may influence the magnitude of the
immune response in human schistosomiasis, including
age, intensity of infection, and the type of Ag used to
assess immune responsiveness. Moreover, increasing age
is associated with an enhanced type 1 immune response
(Ribeiro de Jesus et al. 1993) and heavy infections (more
than 200 eggs/g stool) are associated with enhanced type
2 response (Araujo et al. 1996). These variables did not
explain the results of the present study, since patients
with degree III hepatic fibrosis made more IL-5 and IL-13
despite the fact that their age were higher than the other
groups, and that they had the lowest intensity of infec-
tion.
Recent studies have pointed out an important role of
IL-13 in the development of liver fibrosis (Chiaramonte et
al. 2001, Monica et al. 2003). Although IL-4 and IL-13 share
the same receptor and many biological activities, there
are functional differences between the two cytokines.
While granuloma formation was partially reduced in IL-4-
deficient mice, blocking IL-13 and the IL-4 receptor in these
animals almost completely abrogated granuloma devel-
opment and tissue fibrosis (Chiaramonte et al. 2001).  Our
data, by showing a correlation between the production of
high levels of IL-13 and the development of more severe
fibrosis, suggests that this cytokine might also play a
significant role in human schistosomiasis fibrosis. A re-
cent study has found a protective effect of IFN-γ in liver
fibrosis in Sudanese S. mansoni-infected subjects (Henri
et al. 2002). Another recent study has also associated low
IFN-γ production with liver fibrosis (Booth et al. 2004). In
fact, earlier studies on schistosomiasis pathology in mice
demonstrated that IFN-γ reduces the cellularity of granu-
lomas, and downmodulates granuloma size (Boros &
Lukacs 1992). These data are in concordance with the
data from the present study, because IFN-γ is the major
type 1 cytokine involved in down modulate T helper type
2 cells.
In contrast to our data that showed increased IL-5 and
IL-13 associated with liver fibrosis and that showed any
significant associations between TNF-α levels and liver
fibrosis, studies in schistosomiasis patients from Africa
showed that patients with more severe hepatic fibrosis
had higher TNF-α in PBMC supernatants (Mwatha et al.
1998, Henri et al. 2002, Booth et al. 2004). The contradic-
tory results might be explained by the differences in the
stages of the disease evaluated in these 2 studies: while
the present study evaluated patients in the pre-
hepatosplenic and early hepatosplenic stages of schisto-
somiasis mansoni, these studies evaluated hepatosplenic
patients. Since the degree III hepatic fibrosis patients are
in the early hepatosplenic phase of disease evolution, it
is possible that the TNF-α is produced in later stages of
the disease. Another possible explanation for the oppos-
ing results of these 2 studies is that the African popula-
tion has a high prevalence of malaria, a protozoan infec-
tion that is known to cause hepatosplenomegaly and also
to induce high levels of TNF-α (Mwatha et al. 1998, Clark
2003, Naus 2003). Further studies are necessary to better
clarify the cytokines involved in advanced stages of
hepatosplenic schistosomiasis, and the role of co-infec-
tions with malaria and other pathogens.
The documentation that IL-10 was found to be higher
in subjects with degree III compared to degrees I and II
hepatic fibrosis was unexpected. IL-10 is a modulatory
cytokine which down regulates macrophage activation,
MHC class I and II expression and reduces activation of
both Th1 and Th2 cells (De Wall-Malefyt et al. 1993). Pre-
vious studies have shown that IL-10 is important to re-
duce pathology of acute schistosomiasis and it is de-
creased in patients with hepatosplenomegaly (Falcão et
al. 1998). Since the patients in the present study were in
the pre-hepatosplenic and early stages of hepatosplenom-
egaly it is possible that the documentation herein of in-
creased levels of IL-10 in patients developing liver fibro-
sis may represent an attempt of this cytokine to down
regulate the high levels of IL-5 and IL-13. The increment
of TGF-β levels during evolution of hepatic lesions and
lack of differences in subjects with degrees I, II, and III
hepatic fibrosis could be due to an intermittent induction
of fibrosis.
The present study presents evidence for a role of type
2 immune response in the development of liver fibrosis in
human schistosomiasis. Since IL-5, IL-10, and IL-13 were
associated with degree III hepatic fibrosis, and IL-5, IL-13
increased significantly in patients who developed more
serious hepatic fibrosis over the course of the study.
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